Treatments in Oncology
RSSArticles
-
Decisional Capacity Is Most Common Issue in Neuro-Oncologic Ethical Consults
For a terminal condition, goals of care need to be identified so they can be honored. If discussions do not happen early, when the patient likely is at his or her peak functional status, it leaves caregivers, families, and physicians with little guidance.
-
Left-Sided Breast Cancer Radiation Therapy and Coronary Artery Disease
A study of breast cancer survivors revealed left breast radiation therapy doubles the subsequent risk of coronary heart disease vs. right-sided radiation.
-
Using Cardiac MRI to Detect Suspected Tumors
Among patients with suspected cardiac tumors, cardiac MRI was highly accurate at distinguishing tumor from thrombus and benign from malignant tumors, using subsequent clinical data over five years of follow-up as the diagnostic standard.
-
Can Left Ventricular Strain Detect Early Cardiac Toxicity of Cancer Chemotherapy?
Using left ventricular peak systolic global longitudinal strain vs. left ventricular ejection fraction to survey patients undergoing potentially cardiotoxic chemotherapy with at least one other risk factor for heart failure showed no difference in the primary endpoint of the difference in ejection fraction between the two groups at one year.
-
Relugolix Tablets (Orgovyx)
Relugolix should be prescribed to adults with advanced prostate cancer.
-
Delayed Screenings Correlate with More Severe Lung Cancer Malignancies
COVID-19 led to canceled or delayed care in 2020 — with consequences.
-
Mixed News for Lung Health
Deaths from lung cancer are on the decline, while deaths from lung clots are on the rise, according to a pair of new reports.
-
Pharmacology Watch
New recommendations for HPV vaccine; guidelines for treatment of essential tremor; updates on smoking cessation drugs; and FDA actions. -
Clinical Briefs in Primary Care Supplement
-
Reduced CNS Metastases in TKI-Treated Renal Cell Carcinoma: Data from a Retrospective Analysis
In an analysis of outcomes for patients treated at M.D. Anderson for metastatic renal cell carcinoma before and since the advent of treatment with tyrosine kinase inhibitors (TKI), the development of brain metastases was shown to be significantly reduced. The authors speculate that TKI treatment is altering the natural history of renal carcinoma.